RxDoctor Payments Data

Heather Heutsche

Family · Poland, OHNPI 1265917538

Payments from drug & device makers

$5,406in general payments, 2019–2025

Across 130 payments — averaging $41.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Tandem Diabetes Care, Inc.$2K
  • Insulet Corporation$741
  • Boehringer Ingelheim$79
  • Ascensia Diabetes Care US Inc.$32
  • BETA Bionics, Inc.$24
  • plus $55 from 4 others

What the payments were for

  • Travel & lodging$2,50246%
  • Food & beverage$2,89253%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,406 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$73,828
Medicare patients
324
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide331$415,600
OzempicSemaglutide330$396,956
JardianceEmpagliflozin320$336,198
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7165$195,158
MounjaroTirzepatide79$103,376
Humulin R U-500 KwikpenInsulin Regular, Human49$90,220
Humulin R U-500Insulin Regular, Human44$80,261
Humalog Kwikpen U-200Insulin Lispro30$70,317
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog94$58,523
Tresiba Flextouch U-100Insulin Degludec64$41,817
HumalogInsulin Lispro126$35,816
Humalog Kwikpen U-100Insulin Lispro125$34,695
Lantus SolostarInsulin Glargine,hum.Rec.Anlog316$32,881
JanuviaSitagliptin Phosphate30$30,902
Insulin Lispro Kwikpen U-100Insulin Lispro122$27,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$12$569,554674 claims
Novo NordiskOzempic, Novolog, Rybelsus$16$428,532401 claims
Boehringer IngelheimJardiance, Tradjenta$79$355,963347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Poland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →